Florence Raynaud is a key member of The Institute of Cancer Research (ICR), where she has worked since 1992. She has been involved in the preclinical development of 20 compounds that were synthesized at the ICR and nominated for clinical development. These include platinum agents, antimetabolites, signal transduction pathway inhibitors and antihormonal agents (including abiraterone).

Her interest lies in optimizing the pharmaceutical properties of new agents to improve their administration schedules. Florence also supports the first-in-human pharmacokinetic studies of some of these drugs in early clinical trials, and she is interested in the evaluation of small-molecule metabolites as markers of whether a drug is successfully hitting its target.